Mon, January 27, 2025
[ Mon, Jan 27th ]: Gizmodo
Chinese AI DeepSeek Deep Sixes OpenAI on the App Store, Stocks Tank
[ Mon, Jan 27th ]: FXStreet
Tech turmoil: DeepSeek disruption sends markets into a tailspin
[ Mon, Jan 27th ]: MSN
What to expect from stock markets ahead of Budget 2025? Kranthi Bathini's take
[ Mon, Jan 27th ]: Indiatimes
Capital Numbers shares list with 4% premium on BSE SME platform
[ Mon, Jan 27th ]: MSN
If You'd Invested $100 in PayPal Stock 10 Years Ago, Here's What It Would Be Worth Today
[ Mon, Jan 27th ]: MSN
Goldman Sachs raises AbbVie stock price target to $208
[ Mon, Jan 27th ]: MSN
Is Boston Scientific (BSX) Among the Best Fundamental Stocks to Buy Now?
[ Mon, Jan 27th ]: Investing
DeepSeek's 'Sputnik moment' prompts investors to sell big AI players
[ Mon, Jan 27th ]: MSN
JMP Securities maintains GENI stock with $11 target
[ Mon, Jan 27th ]: MSN
JMP Securities maintains $14 target on Inspired Entertainment stock
[ Mon, Jan 27th ]: MSN
AI proxy stocks Siemens Energy, Munster tumble on DeepSeek concerns
[ Mon, Jan 27th ]: MSN
JMP INITIATES COVERAGE ON DIGITAL INFRASTRUCTURE STOCKS
[ Mon, Jan 27th ]: AOL
1 Unstoppable ETF That Could Turn $350 per Month Into $1 Million
[ Mon, Jan 27th ]: MSN
Prediction: These 2 "Magnificent Seven" Stocks Wi .. est Winners by 2030 (Hint: Neither One Is Nvidia)
[ Mon, Jan 27th ]: MSN
Does This New Bullish Tailwind for Dogecoin Make It a Buy?
[ Mon, Jan 27th ]: MSN
3 of the best Australian stocks to buy now
[ Mon, Jan 27th ]: MSN
Motilal Oswal Innovation Opportunities Fund and 7 .. tual fund NFOs to open for subscription this week
[ Mon, Jan 27th ]: AOL
2 Vanguard ETFs to Buy With $500 and Hold Forever
[ Mon, Jan 27th ]: MSN
2 High-Yield Dividend Stocks to Buy With $300 and Hold Forever
[ Mon, Jan 27th ]: MarketWatch
Stock Market Today: Dow, S&P 500 set to fall, Nas .. ek worries; Nvidia, ASML, Microsoft shares rocked
[ Mon, Jan 27th ]: MSN
Lure of diversification, higher returns and globa .. ving Indian investors to US markets: Subho Moulik
[ Mon, Jan 27th ]: Forbes
5 Promising High-Growth Sectors To Invest In 2025
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of Veru Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of TomTom N.V. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. of TriSalus Life Sciences, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. f Duos Technologies Group, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of Evaxion Biotech A/S in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. g of Alaunos Therapeutics, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. Webstar Technology Group, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of NextPlat Corp in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ing of Suzuki Motor Corporation in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ng of Jasper Therapeutics, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ISeKey International Holding AG in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ing of Data Storage Corporation in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. g of BioXcel Therapeutics, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of AM TELNET CORP in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ng of Surge Battery Metals Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. lling of Mast Therapeutics Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of comScore, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. elling of Selectis Health, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of VELTI in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of United Lithium Corp. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of Dimon Inc in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ng of Unity Biotechnology, Inc. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial selling of Turbo Energy, S.A. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. estar Automotive Holding UK PLC in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ng of North Peak Resources Ltd. in recent trading
[ Mon, Jan 27th ]: WOPRAI
As of Jan 27th, 2025, there has been substantial .. ng of Cidara Therapeutics, Inc. in recent trading

Goldman Sachs raises AbbVie stock price target to $208

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. chs-raises-abbvie-stock-price-target-to-208.html
  Print publication without navigation Published in Stocks and Investing on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the pharmaceutical company's shares to $208.00, up from the previous target of $205.00.
Goldman Sachs has increased its price target for AbbVie Inc. to $208 from $173, maintaining a "buy" rating on the stock. This adjustment reflects optimism about AbbVie's future performance, particularly due to the potential of its new drug, Skyrizi, which is expected to drive significant revenue growth. The stock has already seen a 10% increase year-to-date, and with the new price target, Goldman Sachs analysts suggest that AbbVie could see further gains, supported by its robust pipeline and strategic market positioning.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/goldman-sachs-raises-abbvie-stock-price-target-to-208/ar-AA1xWese ]